Background: IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the general population. There is accumulating evidence that immunosuppressive treatment is efficacious in IgAN. However, it is critical to define appropriate indicators for this therapy especially in the wake of potentially deleterious side effects to immunosuppressives. Methods: This study retrospectively reviewed IgAN cases collected since 1981 to identify clinical and/or histological parameters for disease progression; 310 patients with biopsy proven IgAN, diagnosed from January 1981 to March 2004, were included. Results: We defined a clinical prognostic index (CPI) using multivariate analysis, which incorporated these clinical/histological parameters. Semiquantitative scores were assigned as follows: 2 points if creatinine (Cr) was >1.4 mg/dL, 1 point if proteinuria was >1 g/24 hr, I point if a patient was affected by hypertension, and 1 point if a patient was older than 30 yrs. Dividing our population into two groups (scores 0-2 = low CPI group; scores 3-5 = high CPI group), we demonstrated a significantly different 10-yr renal survival rate; in the low CPI group, renal survival since time of biopsy at 10 yrs was 91.7%; in the high CPI group the renal survival at 10 yrs was 35%. We validated the CPI in an independent sample from Verona (validation group) and demonstrated similar results for the CPI. Conclusions: The CPI is convenient to use for defining the risk of disease progression.

A validated model of disease progression in IgA nephropathy / Magistroni, Riccardo; L., Furci; M., Leonelli; M., Masellis; Ligabue, Giulia; L., Lucchi; A., Lupo; B., Brezzi; G., Gambaro; L., Manganelli; G., Pedrazzi; M., Ricardi; L., Bormioli; Albertazzi, Alberto. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1121-8428. - STAMPA. - 19:1(2006), pp. 32-40.

A validated model of disease progression in IgA nephropathy

MAGISTRONI, Riccardo;LIGABUE, Giulia;ALBERTAZZI, Alberto
2006

Abstract

Background: IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the general population. There is accumulating evidence that immunosuppressive treatment is efficacious in IgAN. However, it is critical to define appropriate indicators for this therapy especially in the wake of potentially deleterious side effects to immunosuppressives. Methods: This study retrospectively reviewed IgAN cases collected since 1981 to identify clinical and/or histological parameters for disease progression; 310 patients with biopsy proven IgAN, diagnosed from January 1981 to March 2004, were included. Results: We defined a clinical prognostic index (CPI) using multivariate analysis, which incorporated these clinical/histological parameters. Semiquantitative scores were assigned as follows: 2 points if creatinine (Cr) was >1.4 mg/dL, 1 point if proteinuria was >1 g/24 hr, I point if a patient was affected by hypertension, and 1 point if a patient was older than 30 yrs. Dividing our population into two groups (scores 0-2 = low CPI group; scores 3-5 = high CPI group), we demonstrated a significantly different 10-yr renal survival rate; in the low CPI group, renal survival since time of biopsy at 10 yrs was 91.7%; in the high CPI group the renal survival at 10 yrs was 35%. We validated the CPI in an independent sample from Verona (validation group) and demonstrated similar results for the CPI. Conclusions: The CPI is convenient to use for defining the risk of disease progression.
2006
19
1
32
40
A validated model of disease progression in IgA nephropathy / Magistroni, Riccardo; L., Furci; M., Leonelli; M., Masellis; Ligabue, Giulia; L., Lucchi; A., Lupo; B., Brezzi; G., Gambaro; L., Manganelli; G., Pedrazzi; M., Ricardi; L., Bormioli; Albertazzi, Alberto. - In: JN. JOURNAL OF NEPHROLOGY. - ISSN 1121-8428. - STAMPA. - 19:1(2006), pp. 32-40.
Magistroni, Riccardo; L., Furci; M., Leonelli; M., Masellis; Ligabue, Giulia; L., Lucchi; A., Lupo; B., Brezzi; G., Gambaro; L., Manganelli; G., Pedra...espandi
File in questo prodotto:
File Dimensione Formato  
06 Magistroni.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 152.14 kB
Formato Adobe PDF
152.14 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/306732
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact